OSCR

Transcriptomic and proteomic insights into progressive myoclonus epilepsy type 1.

Overview

  1. Folkhälsan Research Center, 00290 Helsinki, Finland
  2. Orion Corporation, 02200 Espoo, Finland
  3. Medicum, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland
  4. Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, 0372 Oslo, Norway
Journal: Disease models & mechanisms, volume 19, issue 4, article dmm052681
Dates: received 25 September 2025; accepted 22 February 2026; published online 5 May 2026; in print April 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.1242/dmm.052681 · PMID 41782446 · PMCID PMC13225231 · OpenAlex W7133988320
Open access: gold, a free copy (OpenAlex)
Categories: genetics / omics (modality), mouse (organism), epilepsy (population)
Methods: Statistics
Keywords: EPM1, Cystatin B, Cstb−/− mouse, Brain, Transcriptomics, Proteomics
MeSH: Myoclonic Epilepsies, Progressive*, Proteome*, Proteomics*, Transcriptome*, Animals, Biomarkers, Brain, Cerebellum, Cystatin B, Gene Expression Profiling, Gene Expression Regulation, Lysosomes, Mitochondria (* major topic)
Topic: Glycogen Storage Diseases and Myoclonus (Biochemistry, Biochemistry, Genetics and Molecular Biology), according to OpenAlex
Funding: Medicinska Understadsfareningen Liv och Halsa; Helsingin Yliopisto; Norges forskningsrad (295910); Business Finland; Sigrid Juséliuksen Säätiö; Sigrid Juseliuksen Saati; Finska Lakaresallskapet; Folkhalsanin Tutkimussaati; Folkhälsanin Tutkimussäätiö; Medicinska Understödsföreningen Liv och Hälsa; Finska Läkaresällskapet
Citations: not cited yet (Europe PMC); 116 references in the paper

Abstract

Progressive myoclonus epilepsy type 1 (EPM1) is a rare neurodegenerative disease caused by partial loss of function of cystatin B (CSTB), a cysteine protease inhibitor with known neuroprotective roles. The disease mechanisms remain largely unsolved, and no treatments are available to control the debilitating myoclonus in EPM1. We investigated the impact of CSTB loss on transcriptome and proteome in three regions of CSTB-deficient (Cstb−/−) mouse brain – the cerebellum, cerebral cortex and hippocampus – during disease progression, providing comprehensive insights into the molecular changes and disease mechanisms. We elucidated three critical pathways as potential therapeutic targets. First, significant upregulation of immune response genes indicates heightened immune activity across all brain regions. Second, consistent downregulation of the oxidative phosphorylation pathway with differential expression of mitochondrial genes implies impaired energy metabolism primarily affecting the cerebellum. Third, upregulation of genes essential for lysosomal function with simultaneous downregulation of genes encoding proteins crucial for lysosomal acidification suggests lysosomal dysfunction as an essential pathogenetic mechanism. By combining proteome with transcriptome data, we identified clusterin, apolipoprotein E, peroxiredoxin 6, cathepsin D and aldolase C as potential biomarkers for disease progression.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 28 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 7 authors, 6 keywords, 13 MeSH terms, 11 funders, 115 references.

Cite

This paper

Malyutina, A., Lund, C., Tegelberg, S., Hakala, P., Nyman, T. A., Lehesjoki, A.-E., & Joensuu, T. (2026). Transcriptomic and proteomic insights into progressive myoclonus epilepsy type 1. Disease models & mechanisms, 19(4), dmm052681. https://doi.org/10.1242/dmm.052681

BibTeX

@article{malyutina2026transcriptomic,
author = {Malyutina, Alina and Lund, Carina and Tegelberg, Saara and Hakala, Paula and Nyman, Tuula A and Lehesjoki, Anna-Elina and Joensuu, Tarja},
title = {{Transcriptomic and proteomic insights into progressive myoclonus epilepsy type 1}},
journal = {Disease models \& mechanisms},
year = {2026},
month = apr,
volume = {19},
number = {4},
pages = {dmm052681},
publisher = {Company of Biologists},
issn = {1754-8403},
doi = {10.1242/dmm.052681},
url = {https://doi.org/10.1242/dmm.052681},
pmid = {41782446},
pmcid = {PMC13225231}
}

RIS

TY - JOUR
AU - Malyutina, Alina
AU - Lund, Carina
AU - Tegelberg, Saara
AU - Hakala, Paula
AU - Nyman, Tuula A
AU - Lehesjoki, Anna-Elina
AU - Joensuu, Tarja
TI - Transcriptomic and proteomic insights into progressive myoclonus epilepsy type 1
T2 - Disease models & mechanisms
J2 - Dis Model Mech
PY - 2026
DA - 2026/04/01
VL - 19
IS - 4
SP - dmm052681
SN - 1754-8403
PB - Company of Biologists
DO - 10.1242/dmm.052681
UR - https://doi.org/10.1242/dmm.052681
LA - en
ER -

CSL-JSON

{
"id": "10.1242/dmm.052681",
"type": "article-journal",
"title": "Transcriptomic and proteomic insights into progressive myoclonus epilepsy type 1",
"container-title": "Disease models & mechanisms",
"author": [
{
"family": "Malyutina",
"given": "Alina"
},
{
"family": "Lund",
"given": "Carina"
},
{
"family": "Tegelberg",
"given": "Saara"
},
{
"family": "Hakala",
"given": "Paula"
},
{
"family": "Nyman",
"given": "Tuula A"
},
{
"family": "Lehesjoki",
"given": "Anna-Elina"
},
{
"family": "Joensuu",
"given": "Tarja"
}
],
"container-title-short": "Dis Model Mech",
"volume": "19",
"issue": "4",
"page": "dmm052681",
"DOI": "10.1242/dmm.052681",
"PMID": "41782446",
"PMCID": "PMC13225231",
"ISSN": "1754-8403",
"publisher": "Company of Biologists",
"URL": "https://doi.org/10.1242/dmm.052681",
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
1
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.3389/fnmol.2022.1069122
Cystatin B deficiency results in sustained histone H3 tail cleavage in postnatal mouse brain mediated by increased chromatin-associated cathepsin L activity.
Journal: Frontiers in molecular neuroscience
In common: mouse, 15 references, 2 authors
[2] doi:10.1126/sciadv.adu3955 [code]
Defective EV-mediated transport of SHH alters neural fate specification in EPM1 epilepsy.
Journal: Science advances
In common: epilepsy, 8 references
[3] doi:10.1038/s41586-024-07260-z
Ancestral allele of DNA polymerase gamma modifies antiviral tolerance.
Journal: Nature
In common: mouse, 7 references, author Tuula A Nyman
[4] doi:10.1007/s12035-023-03812-y
Pathological Deficit of Cystatin B Impairs Synaptic Plasticity in EPM1 Human Cerebral Organoids.
Journal: Molecular neurobiology
In common: epilepsy, 7 references
[5] doi:10.1186/s12974-021-02302-z
Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression.
Journal: Journal of neuroinflammation
In common: genetics / omics, mouse, 8 references
[6] doi:10.1038/s42255-025-01367-x [code]
DDHD2 provides a flux of saturated fatty acids for neuronal energy and function.
Journal: Nature metabolism
In common: mouse, 1 reference, author Tuula A Nyman
[7] doi:10.1371/journal.pbio.3003318 [code]
Lineage trajectories and fate determinants of postnatal neural stem cells and ependymal cells in the developing ventricular zone.
Journal: PLoS biology
In common: mouse, 4 references
[8] doi:10.1093/stmcls/sxac069
Deciphering the Transcriptional Landscape of Human Pluripotent Stem Cell-Derived GnRH Neurons: The Role of Wnt Signaling in Patterning the Neural Fate.
Journal: Stem cells (Dayton, Ohio)
In common: author Carina Lund
[9] doi:10.1186/s12974-023-02814-w
Experimental hepatic encephalopathy causes early but sustained glial transcriptional changes.
Journal: Journal of neuroinflammation
In common: genetics / omics, mouse, 5 references
[10] doi:10.1091/mbc.e25-07-0346
The hereditary spastic paraplegia type 21 (SPG21) protein is a RAB7A effector that promotes noncanonical mTORC1-catalyzed TFEB phosphorylation and cytoplasmic retention.
Journal: Molecular biology of the cell
In common: mouse, 3 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.